Idelalisib for the treatment of indolent non-Hodgkin's lymphoma

Drugs of Today

Volumn 50, Issue 2, 2014, Pages 113-120

  Lopez, J P ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Idelalisib; Indolent non Hodgkin's lymphoma; INHL; Non Hodgkin's lymphoma; Phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit delta isoform (PI3K ) inhibitor; Tyrosine kinase inhibitor

Indexed keywords

IDELALISIB;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; DRUG METABOLISM; DRUG SCREENING; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

IDELALISIB; INDOLENT NON-HODGKIN'S LYMPHOMA; INHL; NON-HODGKIN'S LYMPHOMA; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM (PI3KΔ) INHIBITOR; TYROSINE KINASE INHIBITOR;

ANIMALS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOMA, NON-HODGKIN; PURINES; QUINAZOLINONES;

EID: 84896092123     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.2.2104040     Document Type: Article

References (31)

1. Armitage, J.O., Weisenburger, D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16(8): 2780-95. (Pubitemid 28363044)
2. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2): 71-96. (Pubitemid 351521864)
3. National Cancer Institute SEER stat fact sheets: non-Hodgkin lymphoma http://seer.cancer.gov/statfacts/html/nhl.html. Accessed January 28, 2014.
4. Anderson, J.R., Armitage, J.O., Weisenburger, D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9(7): 717-20. (Pubitemid 28394156)
5. Lunning, M.A., Vose, J.M. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012, 26(6): 279-88.
6. Shankland, K.R., Armitage, J.O., Hancock, B.W. Non-Hodgkin lymphoma. Lancet 2012, 380(9844): 848-57.
7. Gribben, J.G. How I treat indolent lymphoma. Blood 2007, 109(11): 4617-26. (Pubitemid 46830597)
8. Jaffe, E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Haematology Am Soc Hematol Educ Program 2009, 523-31.
9. Imrie, K.R., Linch, D.C., Czuczman, M.S. Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma. Anticancer Drugs 2002, 13(Suppl. 2): S19-24. (Pubitemid 36181533)
10. Maloney, D.G., Grillo-Lopez, A.J., White, C.A. et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90(6): 2188-95. (Pubitemid 27392702)
11. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16(8): 2825-33. (Pubitemid 28363048)
12. Foran, J.M., Rohatiner, A.Z., Cunningham, D. et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18(2): 317-24. (Pubitemid 30056420)
13. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M., Miller, T.P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23(33): 8447-52.
14. Xu, Z.Z., Xia, Z.G., Wang, A.H., Wang, W.F., Liu, Z.Y., Chen, L.Y., Li, J.M. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol 2013, 92(10): 1351-8.
15. Schatz, J.H. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep 2011, 13(5): 398-406.
16. Lannutti, B.J., Meadows, S.A., Herman, S.E. et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117(2): 591-4.
17. Herman, S.E., Gordon, A.L., Wagner, A.J. et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(12): 2078-88.
18. Hoellenriegel, J., Meadows, S.A., Sivina, M. et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118(13): 3603-12.
19. Meadows, S.A., Vega, F., Kashishian, A. et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012, 119(8): 1897-1900.
20. nd Annu Meet Am Soc Hematol (ASH) (December 4-7, Orlando) 2010, Abst 1774.
21. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 7003.
22. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8519.
23. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8526.
24. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8500.
25. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst TPS7133.
26. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 7005.
27. A study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (NCT01732923). ClinicalTrials.gov Web site, Accessed January 28, 2014.
28. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 7017.
29. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 7005.
30. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst TPS8617.
31. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst TPS7131.